Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating

CG Oncology, Inc. (NASDAQ:CGON) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 17, Morgan Stanley raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52, while maintaining an Overweight rating on the shares.

A researcher in a laboratory examining a vial of oncolytic herpes simplex virus, demonstrating the company’s commitment to finding a cure for cancer.

The firm told investors in a research note that although the non-muscle invasive bladder cancer space has undergone recent and anticipated approvals, the space is comprehensive enough to accommodate multiple players. It thus considers cretostimogene to be meaningfully differentiated by its safety data and durability, along with having “best-in-disease potential” that supports an optimistic rating for the company.

CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.